Navigation Links
OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib
Date:3/18/2008

first siRNA to enter a Phase III pivotal trial and now, one of the first siRNAs to receive a U.S. patent covering its broad therapeutic use. This second issued patent covering bevasiranib and its anti-VEGF applications further reinforces our confidence in our strong and growing intellectual property position in this important space. "

The newly issued patent is exclusively licensed to OPKO on a worldwide basis through an agreement with the University of Pennsylvania.

Bevasiranib is a first-in-class siRNA drug designed to silence the genes that produce vascular endothelial growth factor, believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase III clinical trials.

The multi-national Phase III COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet AMD is currently enrolling patients at multiple clinical sites. For more information about the COBALT trial, please visit http://www.opko.com/clinicaltrials.

About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after successfully completing Phase II trials for wet age-related macular degeneration and diabetic macular edema. OPKO is developing a preclinical pipeline of novel agents for ophthalmic diseases, and it markets innovative diagnostic imaging systems that complement the company's therapeutic products. For more information visit the company's website at http://www.opko.com.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identi
'/>"/>

SOURCE OPKO Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... COPENHAGEN, Denmark , Sept. 16, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... its ongoing Phase 2 pediatric study to evaluate ... hormone deficiency, or GHD.  The full interim results ... of the GRS and IGF Society, being held ...
(Date:9/15/2014)... drives classical phase transitionsthink solid, liquid, and ... the temperature drops. If phase transitions occur ... mechanics reigns, subtle fluctuations can dramatically transform ... U.S. Department of Energy,s Brookhaven National Laboratory ... frigid landscape of absolute zero to isolate ...
(Date:9/15/2014)... have developed a technique for controlling the surface tension ... the door to a new generation of reconfigurable electronic ... the fact that the oxide "skin" of the metal ... as a surfactant, lowering the surface tension between the ... a liquid metal alloy of gallium and indium. In ...
(Date:9/15/2014)... IRVINE, Calif. , Sept. 15, 2014 /PRNewswire/ ... a new viral transport solution for safe ambient ... prior to molecular testing. Importantly, the infectivity of agents ... solution while maintaining the integrity of the viral ... news of the recent Ebola epidemic in ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Researchers control surface tension to manipulate liquid metals 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3
... programs for the University of Wisconsin-Madison, is part information technologist, ... Part II of this interview. In Part I , ... (below), he addresses creating a culture of innovation and finding ... featured speaker at the Fusion 2007 CEO-CIO Symposium . ...
... In a move that could bring additional investment partners to ... an office in Ann Arbor, Mich. after receiving money from ... which recently moved into a larger space in the MGE ... of three venture firms selected to receive funding through a ...
... - Oskar Anderson, chief information officer for the Wisconsin ... succeed Matt Miszewski as administrator of the state Division ... this week, will join the Department of Administration ... His appointment was confirmed this morning in an e-mail to ...
Cached Biology Technology:Venture Investors to open Michigan office 2Oskar Anderson to succeed Miszewski as head of state technology division 2
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
(Date:9/16/2014)... returned to Spain culminating the around the world of ... of how the global ocean works and what is ... the atmosphere is not limited to coastal areas, but ... planet, and it is already affecting the ocean ecosystem. ... CSIC Residence for Researchers in Barcelona, in a congress ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... research team from Rollins College in Florida and the University ... the coral-killing pathogen that causes white pox disease of Caribbean ... elkhorn coral was listed for protection under the United States ... disease. The team,s findings have just been published in the ...
... A recent study demonstrated increased rates of celiac disease ... in the May-June 2011 issue of The Journal ... patients presenting with infertility. Each participant underwent serologic ... testing. The 4 patients who had positive serum ...
... , Cincinnati, (OH) - The International Rett Syndrome Foundation ... to support eight cutting-edge projects that aim to accelerate ... IRSF is the world,s largest private source of funding ... 1998, IRSF has cumulatively funded over $24M in high ...
Cached Biology News:Human pathogen killing corals in the Florida Keys 2Human pathogen killing corals in the Florida Keys 3IRSF awards over $650,000 for Translational Rett Syndrome research 2
... Our Accumix standard is a new tuning ... electrospray ionization mass spectrometry. Accumix is ... mass range coverage for both tuning and ... and LTQ-MS) and Fourier transform mass spectrometers. ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Biology Products: